Comparison of Quality of Life (QoL) Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Peritoneal Cancer

Trial Profile

Comparison of Quality of Life (QoL) Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Peritoneal Cancer

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Trabectedin (Primary) ; Carboplatin; Doxorubicin liposomal; Gemcitabine; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms COMPASS
  • Most Recent Events

    • 05 Dec 2017 Status changed from not yet recruiting to active, no longer recruiting.
    • 02 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top